Lamin is a structural protein of the nuclear lamina. Lamin A is a type A lamin encoded by the LMNA gene. Lamin A contains 664 amino acids and is expressed in most somatic cells. It contains α-helical rod domain to enable assembly into filaments, a nuclear localization sequence, and a carboxy-terminal CAAX box isoprenylation sequence for nuclear membrane targeting.
synthetic peptide corresponding to amino acids 598-611 of human lamin A with a C-terminal added cysteine, conjugated to KLH. The corresponding sequence differs by one amino acid in rat, three amino acids in mouse, and by a gap of one amino acid in both rat and mouse lamin A.
Anti-Lamin A (C-terminal) antibody is suitable for use in western blot (0.1-0.2 μg/mL) using HeLa nuclear extract. This antibody can also be used in indirect immunofluorescence (1-2 μg/mL) using HeLa cells, rat NRK and mouse 3T3 cells. Additionally, anti-Lamin A (C-terminal) antibodies are suitable for use in immunoblotting (approx. 70 kDa). Cleaved fragments of lamin A may form additional bands at 45-50 kDa.
Anti-Lamin A (C-terminal) antibody produced in rabbit has been used in:
- western blotting
- immunofluorescence microscopy
Lamin A cut into a 47kDa fragment that facilitates chromatin condensation and nuclear degradation during cell death
Mutations in lamin A and C have been linked to a variety of rare human diseases including muscular dystrophy, lipodystrophy, cardiomyopathy, neuropathy, and progeroid syndromes (collectively termed laminopathies) and to premature aging (Hutchinson-Gilford progeria syndrome).
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.